Ignite Creation Date:
2024-05-06 @ 12:37 AM
Last Modification Date:
2024-10-26 @ 10:52 AM
Study NCT ID:
NCT01619046
Status:
UNKNOWN
Last Update Posted:
2014-07-03
First Post:
2012-05-31
Brief Title:
Safety Efficacy and Pharmacokinetics of GreenGene F to Previously Treated Patients With Severe Hemophilia A
Sponsor:
Green Cross Corporation
Organization:
GC Biopharma Corp
Study Overview
Official Title:
Determination of Safety Efficacy and Pharmacokinetics of GreenGene F in Previously Treated Patients 12 Years of Age or Older Diagnosed With Severe Hemophilia A
Status:
UNKNOWN
Status Verified Date:
2014-07
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to assess the safety efficacy and pharmacokinetics of GreenGene F in subjects with severe hemophilia A previously treated 150 exposure days with a Factor VIII concentrate and without presence or history of inhibitors to FVIII Factor VIII
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None